The Complete Success in Refractory Mooren’s Ulcer Treated with Infliximab

ABSTRACT

Purpose

To describe the management and outcome of two extremely rare and painful cases of Mooren’s ulcer, an idiopathic peripheral autoimmune-associated ulcerative corneal disease.

Methods

Case report with literature review on the management of ocular inflammation in Mooren’s ulcer.

Results

A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren’s ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups.

Conclusion

This case report highlights how infliximab can be effective in cases with Mooren’s ulcer refractory to conventional therapies.

KEYWORDS:

• Anti-tumor necrosis factor alpha
• immunosuppresion
• infliximab
• Mooren’s ulcer
• peripheral ulcerative keratitits

Acknowledgments

This case report was presented as an e-poster in XXXIII Congress of the European Society of Cataract and Refractive Surgeons. Each author made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data, drafted the article or revised it critically for important intellectual content, approved the version to be published, and had participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.